Objectives

1.Describe how GLP-1 agonists delay gastric emptying and why this increases the risk of retained gastric contents despite standard "nothing by mouth" (NPO) fasting times.

 2: Identify GLP-1 agonist medications that are used in the pediatric population for Type 2 diabetes and/or weight management.

 “To view additional information on the Nemours Children’s disclosure policy, right click on this link to open in a new window.”

All relevant financial relationships have been mitigated.

This Microsoft Teams service includes a feature that allows audio and any documents and other materials exchanged or viewed during the session to be recorded. By joining this session, you automatically consent to such recordings. If you do not consent to the recording, discuss your concerns with the meeting host prior to the start of the recording or do not join the session. Please note that any such recordings may be subject to discovery in the event of litigation.